Novo Nordisk reports positive data in diabetes trials

Denmark's Novo Nordisk has seen its shares surge on the news that Liraglutide has produced positive results in two late-stage trials, positioning it for regulatory approval next year. The two Phase III trials are the second and third legs among five late-stage studies of the drug. And in these two steps the drug reduced weight and improved glucose control. Roughly 40 percent of patients hit the American Diabetes Association's goal of average blood glucose control (HbA1c) of 7 percent.

"The encouraging clinical results from the two new trials confirm the positive effect of Liraglutide...and leave us confident that we are on track to submit for regulatory approval mid-2008," said Novo Nordisk chief science officer Mads Krogsgaard Thomsen.

- check out the release
- read the report from the PharmaTimes

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.